Tourmaline Bio company information, Employees & Contact Information

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer Novartis

Novartis to Acquire Tourmaline Bio for $1.4 Billion, Enhancing Cardiovascular Treatment Portfolio Quiver Quantitative

Tourmaline Bio To Be Acquired By Novartis AG For $1.4 Billion citybiz

Novartis to buy Tourmaline Bio, gaining promising heart medicine statnews.com

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis

$1.4 Billion Deal: Novartis Acquires Tourmaline Bio's Breakthrough Anti-Inflammatory Heart Disease Drug Stock Titan

Novartis to acquire Tourmaline Bio for $1.4 billion Reuters

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition Yahoo Finance

Novartis Acquiring Tourmaline Bio for Cardiovascular Disease Treatment Pacibekitug Pharmaceutical Executive

Novartis Agrees to Buy Tourmaline Bio for $48 Per Share in Cash Bloomberg.com

Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease Nasdaq

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease GlobeNewswire

Tourmaline Bio, Inc. Reports Positive Phase 2 Results for Pacibekitug in Reducing Inflammatory Biomarkers at ESC Congress 2025 Quiver Quantitative

First-Ever 85% CRP Reduction with Quarterly Dosing: Tourmaline's Breakthrough in Heart Disease Trial Stock Titan

Tourmaline Bio, Inc. Confirms Progress in Phase 2 TRANQUILITY Trial and Financial Position Ahead of Key Data Readout Nasdaq

Tourmaline Bio, Inc. Reports Positive Phase 2 TRANQUILITY Trial Results for Pacibekitug and Financial Highlights for Q2 2025 Quiver Quantitative

Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care Stock Titan

TRML Stock Price and Chart — NASDAQ:TRML TradingView

Novartis to buy US biotech Tourmaline Bio for US$1.4 billion The Business Times

Novartis to gain heart drug in $1.4B deal for Tourmaline Bio BioPharma Dive

Tourmaline Bio (TRML): Assessing Valuation as Market Interest Grows Yahoo Finance

Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal Yahoo Finance

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition Yahoo Finance

Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know Yahoo Finance

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion Deal - WSJ The Wall Street Journal

Novartis Buys Tourmaline Bio, Setting Up Showdown With Novo Nordisk Citeline News & Insights

Tourmaline Bio Reports Loss as R&D Rises Nasdaq

Novartis to acquire Tourmaline Bio The Pharma Letter

Novartis to acquire Tourmaline Bio in $1.4B all-cash deal (NVS:NYSE) Seeking Alpha

Novartis AG Buys Tourmaline Bio in $1.4B Deal The Healthcare Technology Report.

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn PMLiVE

Tourmaline Bio To Be Acquired By Novartis; Was TRML Stock In Your Investment Portfolio? RTTNews

Novartis Inks $1.4 Billion Deal. Why It Just 'Makes Sense.' Investor's Business Daily

Novartis buys US biotech Tourmaline Bio for USD 1.4bn medwatch.com

Novartis acquires Tourmaline Bio in deal worth $1.4B PharmaLive

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition Seeking Alpha

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened Stocktwits

Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday Benzinga

Novartis to buy Tourmaline Bio for $1.4 billion The Economic Times

Switzerland: Novartis to acquire Tourmaline Bio for US$1.4bn Investors in Healthcare

Novartis To Acquire Tourmaline Bio in $1.4B Deal to Boost Heart Drug Pipeline USA Herald

Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data Seeking Alpha

Tourmaline Bio announces CMO resignation Investing.com

Tourmaline Bio announces FDA clearance of Investigational New Drug application for TOUR006 Ophthalmology Times

Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish (NASDAQ:TRML) Seeking Alpha

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement GlobeNewswire

Talaris Therapeutics to merge with Tourmaline Bio Pharmaceutical Technology

Tourmaline Bio, Talaris Therapeutics Announce Reverse Merger in Stock Deal BioSpace